Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
ALB-TRIAL celebrates 50% enrollment milestone
The ALB-TRIAL, MICROB-PREDICT's clinical study, has reached the halfway milestone: 50% of the planned 240 patients are now enrolled! Congratulations to everyone involved. Recruitment has taken place at 14 active centres across seven European countries, marking a major step forward for the trial. The ALB-TRIAL is a European, double-blinded, placebo-controlled clinical study. Its goal is to explore whether a novel biomarker can help predict which patients with cirrhosis and ascites benefit most from long-term human albumin infusions.
More news7th GA Meeting in Cologne, Germany from 27-29 January 2025!
A huge thank you to everyone for sharing their latest results and project updates! Together we also celebrated exciting progress in our clinical study: MICROB-PREDICT’s ALB-TRIAL has hit a major milestone in January, with 25% of the targeted 240 patients enrolled across nine active centers in Europe, with more sites joining soon!
And of course, we wrapped it up with some after-work fun, exploring Cologne with a ScienceRallye!
MICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news